MRNA · News · 20260731N
Operating Expense Trends
Moderna, Inc. · 2026-07-31 · Importance 64 · Surprise 42 · In source text
Moderna improved its 2026 GAAP operating expense outlook by approximately $200 million from its previous estimate. The company said it is continuing to reduce costs while advancing programs in respiratory vaccines, oncology and rare diseases. Moderna reported a second-quarter GAAP net loss of $782 million, or $1.97 per share.
Key facts
- Moderna improved its 2026 GAAP operating expense outlook by approximately $0.2 billion from its previous estimate. source
- Moderna reported a GAAP net loss of $(0.8) billion for the second quarter of 2026. source
- Moderna reported a net loss of $782 million, or $1.97 per share, for Q2 2026. source
- Moderna's six-month net loss widened to $2.125 billion. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | positive | probable | +69.0% | Moderna improved its 2026 GAAP operating expense outlook by approximately $0.2 billion from its previous estimate. |
| net_income | negative | realized | — | Moderna reported a net loss of $782 million, or $1.97 per share, for Q2 2026. |
| net_income | negative | realized | — | Moderna's six-month net loss widened to $2.125 billion. |